Issue 121

Psilocybin therapy in the treatment of methamphetamine and opioid use disorders

In the last year, three million people in the United States have struggled with opioid use disorder, and another 1.5 million people have dealt with methamphetamine misuse. The Psychedelics as Medicine Report revealed opioid use disorder alone costs the US economy US$227 billion a year.

In 2020, over 56,000 deaths involving synthetic opioids were recorded, largely due to the widespread use of fentanyl in the illicit drug supply. This equates to more American lives lost than in the entirety of the Vietnam War.

To discuss clinical trials into the treatment of opioid use disorder and methamphetamine misuse, PSYCH spoke with Professor Paul Hutson, a co-investigator for both psilocybin studies at University of Wisconsin–Madison.

AN EXPLORATION OF PSYCHEDELIC MEDICINES IN WOMEN'S HEALTH

Nina Patrick and Natasha Antropova review the science behind the use of psychedelic medicines in women’s health.

CYBIN PROVIDES UPDATE ON DRUG DEVELOPMENT PROGRAMMES

Psychedelic Health spoke with Cybin’s CEO, Doug Drysdale, on progress made with the company’s deuterated psychedelic compounds.

BUSINESS AND INVESTMENT

GH Research reports 2022 financial results. It has a Phase II 5-MeO-DMT study and a cash position of US$251.7m.

Reunion Neuroscience sues Mindset Pharma. The company claims it knowingly copied its 4-OH-DiPT prodrug.

Inside the implosion of Synthesis Institute. Not one student had completed its Oregon facilitator programme.

Small Pharma release data from Phase II DMT study. Improvement in anxiety suggests potential in new indications.

BetterLife Closes C$1.8m private placement. The organisation is developing non-hallucinogenic LSD analogues.

Psychedelic medicines in relationship counselling. TIME Magazine explores the rise of MDMA-assisted couples therapy.

On Thursday, 6 July, industry leaders will converge at the iconic British Museum for PSYCH Symposium: London 2023.

Early Bird tickets on sale for £299 + VAT.

TICKET REGISTRATION

SCIENCE AND RESEARCH

The serotonin hypothesis of depression. The notion of a chemical imbalance has shaped the way we view mental illness.

Psychedelic medicines and the activation of serotonin receptors. Serotonin affects cognition, perception and emotions.

How psychedelic drugs may help with depression. Understanding mechanisms of action could lead to better treatments.

With contributions from Awakn, Cybin and Psyence, The Psychedelics as Medicine Report: Fourth Edition empowers investors to make informed decisions.

COMPLIMENTARY DOWNLOAD

REGULATION AND LEGISLATION

UK campaign to reschedule psilocybin. Crispin Blunt MP, who advises Psych Capital, calls on the government to reclassify psilocybin.

EMA plans psychedelic healthcare workshop. The regulator has recognised developments in psychedelic medicine.

Vermont lawmakers file decriminalisation bills . A standalone psilocybin bill has been referred to the senate committee.

Would your organisation benefit from engaging with Europe’s psychedelic medicine community?

Event partnership provides the opportunity to engage with an audience ready to support the development of psychedelic healthcare.

Previous partners include COMPASS Pathways, Beckley Psytech and Awakn Life Sciences.

PARTNERSHIP OPPORTUNITIES

ARTICLES OF INTEREST

Increase in mental health callouts received by police. Every UK police force has reported a rise since 2017.

Three-quarters of children detained under mental health act are girls. Analysis highlights worrying gender differences.

Do you know a spokesperson who could provide insights on the future of psychedelic healthcare?

Previous symposium speakers include:

Rick Doblin – Founder, MAPS
Cosmo Feilding Mellen – CEO, Beckley Psytech
Carol Routledge – Chief Medical and Scientific Officer, Small Pharma
MP Crispin Blunt – Chair, The Conservative Drug Policy Reform Group

SPEAKING OPPORTUNITIES